None
Quote | Nutriband Inc. (OTCMKTS:NTRB)
Last: | $6.69 |
---|---|
Change Percent: | -23.54% |
Open: | $5.48 |
Close: | $6.69 |
High: | $7.2 |
Low: | $4.9 |
Volume: | 2,150,626 |
Last Trade Date Time: | 10/01/2021 04:55:28 pm |
News | Nutriband Inc. (OTCMKTS:NTRB)
Nutriband (NASDAQ: NTRB, NTRBW) , a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN , a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. A...
LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Nutriband Inc. (NASDAQ: NTRB) , a pharmaceutical company with a specific focus on transdermal technologies, today announces it has selected IBN , a multifaceted financial news and publishing company for private and publi...
Message Board Posts | Nutriband Inc. (OTCMKTS:NTRB)
Subject | By | Source | When |
---|---|---|---|
New 52 week lows geez. Whats going on? | Inve$tor77 | investorshub | 06/20/2023 2:52:52 PM |
$2.50s. Looking for a nice bounce possibly . | Inve$tor77 | investorshub | 06/20/2023 2:13:45 PM |
Price trading up | LionsPride | investorshub | 06/19/2023 8:37:13 PM |
news all the way baby | StocksNcash | investorshub | 06/19/2023 11:51:59 AM |
Price now | Seriously folks | investorshub | 06/17/2023 9:15:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Nutriband (NASDAQ: NTRB, NTRBW) , a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN , a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. A...
LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Nutriband Inc. (NASDAQ: NTRB) , a pharmaceutical company with a specific focus on transdermal technologies, today announces it has selected IBN , a multifaceted financial news and publishing company for private and publi...
Nutriband (NASDAQ: NTRB, NTRBW) , a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has closed an $8.4 million private placement to fund the commercial development program for its lead product, AVERSA(TM) Fentanyl. AVERSA Fentanyl ha...